Dupont Capital Management’s MacroGenics MGNX Stock Holding History

Dupont Capital Management’s Portfolio MGNX Stock Details MGNX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-8,697	Closed	-$140K	–	1731
2021 Q4	$140K	Sell	8,697 -3,468	-29%	-$65.3K	0.01%	1231
2021 Q3	$255K	Buy	+12,165	New	+$293K	0.01%	1129
2016 Q4	–	Sell	-26,768	Closed	-$801K	–	847
2016 Q3	$801K	Buy	+26,768	New	+$796K	0.02%	503

Other funds holding MGNX

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Dupont Capital Management's MGNX Position: Q1 2022 in Review

Dupont Capital Management sold out of MacroGenics (MGNX) in Q1 2022, closing a stake of 8,697 shares — an estimated $140K sold.

Dupont Capital Management first reported a position in MGNX in Q3 2016 and held it in 3 quarters. The position peaked at $801K in Q3 2016. 144 funds tracked by Wall St. Rank hold MGNX as of Q1 2022.

Dupont Capital Management reported no remaining MacroGenics position as of Q1 2022 after selling out during the quarter.
Dupont Capital Management sold 8,697 MacroGenics shares in Q1 2022, an estimated $140K.
Dupont Capital Management first reported a position in MacroGenics in Q3 2016 and held it in 3 quarters.
Dupont Capital Management's MacroGenics position peaked at $801K in Q3 2016.
144 funds tracked by Wall St. Rank held MacroGenics as of Q1 2022.

Based on Dupont Capital Management's 13F filing for Q1 2022, filed 27 Apr 2022.